Current price levels make obesity drugmaker Arena Pharmaceuticals an attractive stock to consider.
Growth prospects make Questcor a solid investment.
Growth opportunity for orphan drug Soliris makes Alexion Pharmaceuticals an attractive investment.
Strong pipeline will allow the company to show continued growth
There is a lot of room for Questcor to grow its revenues.
Obesity drug Contrave will prove to be a game changer for Orexigen.
An Impressive pipeline can be a strong asset for Alnylam Pharmaceuticals.
The obesity-drug sector is becoming a battle ground.
Future growth prospects indicate that the biotech stock is still undervalued.